#ESMO26 Dr. @ShaodongHong with phase II study of 1L BAT8008 (TROP2-ADC) + BAT1308 (PD1) in NSCLC. TRAEs include myelosuppression, stomatitis. RR 61% (47% in PDL1 negative, 59% in l

Stephen V Liu, MD· @StephenVLiu · X·2026-10-24 15:38· 1 day agoScore70

Body

#ESMO26 Dr. @ShaodongHong with phase II study of 1L BAT8008 (TROP2-ADC) + BAT1308 (PD1) in NSCLC. TRAEs include myelosuppression, stomatitis. RR 61% (47% in PDL1 negative, 59% in low, 83% in high). mPFS 12m (7.7m in squamous, NR for non-squamous).

88 views · 1 like · 0 reposts · 0 replies

Conference abstracts

2631ROmatched by Rapid oral 1: NSCLC, metastatic

First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study

https://esmocongress.esmo.org

Source: Stephen V Liu, MD · x.com